InnoCan Pharma Corporation (INNPF) Fair Value & Analysis

Consumer Defensive · US · Market cap $10.8M

Below-average quality, screening 75% undervalued on our models.

What matters now

• The price is below even our cautious bear case ($2.08). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

60‑month range $0.1200 – $82.59 · fair‑value band $2.08 – $2.91 · the $1.43 price screens below the $2.50 fair value. Dashed = 300-day average. As of Jul 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

InnoCan Pharma Corporation (INNPF) currently trades at $1.43, while our model-based Fair Value estimate is $2.50, implying the stock looks roughly 74.8% undervalued today. The Quality Score stands at 45/100 (below-average quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, InnoCan Pharma Corporation generated revenue of $25.3M at a net margin of -6.0%. Revenue declined 17.1% year over year. It earns a return on equity of -13.5%. The balance sheet holds a net cash position of $5.0M. Fundamentals as of Jul 24, 2026

Our scenario range runs from $2.08 (bear case) to $2.91 (bull case); at $1.43, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at 75%, INNPF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth DCF ($3.19) versus Asset-Based ($0.8300). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations.

Full company description

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

InnoCan Pharma Corporation reported revenue of $26.6M in FY2025 versus $196K in FY2021, a compound +241.4%/yr. Reported net income was −$1.1M in FY2025.

Watch INNPF: get an alert when its fair value changes →

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Household & Personal Products median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.